BSE:506820

Stock Analysis Report

Executive Summary

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and distributes pharmaceutical products in India and internationally.

Snowflake

Fundamentals

Outstanding track record with flawless balance sheet.


Similar Companies

Share Price & News

How has AstraZeneca Pharma India's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.8%

506820

2.1%

IN Pharmaceuticals

1.6%

IN Market


1 Year Return

28.9%

506820

-21.1%

IN Pharmaceuticals

0.8%

IN Market

Return vs Industry: 506820 exceeded the Indian Pharmaceuticals industry which returned -21.1% over the past year.

Return vs Market: 506820 exceeded the Indian Market which returned 0.8% over the past year.


Shareholder returns

506820IndustryMarket
7 Day1.8%2.1%1.6%
30 Day2.9%-6.9%1.5%
90 Day8.6%-7.2%-3.3%
1 Year28.9%28.9%-20.4%-21.1%2.7%0.8%
3 Year124.7%124.5%-26.3%-27.8%22.0%16.0%
5 Year164.7%164.6%-11.1%-13.8%42.3%29.3%

Price Volatility Vs. Market

How volatile is AstraZeneca Pharma India's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is AstraZeneca Pharma India undervalued compared to its fair value and its price relative to the market?

78.16x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: 506820 (₹2174.9) is trading above our estimate of fair value (₹287.42)

Significantly Undervalued: 506820 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 506820 is poor value based on its PE Ratio (78.2x) compared to the Pharmaceuticals industry average (15.4x).

PE vs Market: 506820 is poor value based on its PE Ratio (78.2x) compared to the Indian market (13.1x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate 506820's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 506820 is overvalued based on its PB Ratio (18.1x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is AstraZeneca Pharma India forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-0.06%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 506820's earnings are forecast to decline over the next 3 years (-0.06% per year).

Earnings vs Market: 506820's earnings are forecast to decline over the next 3 years (-0.06% per year).

High Growth Earnings: 506820's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 506820's revenue (10.8% per year) is forecast to grow slower than the Indian market (11.4% per year).

High Growth Revenue: 506820's revenue (10.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if 506820's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has AstraZeneca Pharma India performed over the past 5 years?

55.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 506820 has become profitable over the past 5 years, growing earnings by 55.2% per year.

Accelerating Growth: 506820's earnings growth over the past year (162.5%) exceeds its 5-year average (55.2% per year).

Earnings vs Industry: 506820 earnings growth over the past year (162.5%) exceeded the Pharmaceuticals industry 16.4%.


Return on Equity

High ROE: 506820's Return on Equity (23.1%) is considered high.


Return on Assets

ROA vs Industry: 506820 has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: 506820 has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is AstraZeneca Pharma India's financial position?


Financial Position Analysis

Short Term Liabilities: 506820's short term assets (₹4.0B) exceeds its short term liabilities (₹2.6B)

Long Term Liabilities: 506820's short term assets (4.0B) exceeds its long term liabilities (20.2M)


Debt to Equity History and Analysis

Debt Level: 506820 is debt free.

Reducing Debt: 506820 had no debt 5 years ago.

Debt Coverage: 506820 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 506820 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: 506820 has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 506820's debt is covered by short term assets.


Next Steps

Dividend

What is AstraZeneca Pharma India's current dividend yield, its reliability and sustainability?

0.091%

Current Dividend Yield


Dividend Yield vs Market

company0.09%marketbottom25%0.6%markettop25%2.5%industryaverage0.9%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: 506820's dividend (0.091%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: 506820's dividend (0.091%) is low compared to the top 25% of dividend payers in the Indian market (2.49%).

Stable Dividend: 506820 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.

Growing Dividend: 506820 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 506820's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

What is the CEO of AstraZeneca Pharma India's salary, the management and board of directors tenure and is there insider trading?

5.2yrs

Average management tenure


CEO

Gagan Bedi (48yo)

2.3yrs

Tenure

₹38,126,383

Compensation

Mr. Gagandeep Singh Bedi also known as Gagan, has been Managing Director of AstraZeneca Pharma India Ltd. since July 1, 2017 and serves as its Country President. Mr. Bedi served as Country President - Phil ...


CEO Compensation Analysis

Compensation vs. Market: Gagan has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Indian market.

Compensation vs Earnings: Gagan's compensation has increased by more than 20% in the past year.


Management Age and Tenure

5.2yrs

Average Tenure

54yo

Average Age

Experienced Management: 506820's management team is seasoned and experienced (5.2 years average tenure).


Board Age and Tenure

2.8yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 506820's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • José Baselga (59yo)

    Executive VP

    • Tenure: 0.8yrs
  • K. Shenoy (63yo)

    Director of Regulatory

    • Tenure: 25.4yrs
    • Compensation: ₹3.05m
  • Ramesh Venkatapathi (67yo)

    Director of Quality Assurance & Technical Services

    • Tenure: 37.9yrs
    • Compensation: ₹2.45m
  • Paurus Irani (52yo)

    Global Medical Affairs Leader - Infection

    • Tenure: 11.2yrs
    • Compensation: ₹9.63m
  • Gagan Bedi (48yo)

    MD, Country President & Executive Director

    • Tenure: 2.3yrs
    • Compensation: ₹38.13m
  • Rajesh Marwaha (56yo)

    CFO & Executive Director

    • Tenure: 2.8yrs
    • Compensation: ₹19.72m
  • Vimlesh Maheshwari

    Finance Controller

    • Tenure: 0yrs
  • Smita Saha (49yo)

    Vice President of Human Resources

    • Tenure: 0yrs
    • Compensation: ₹12.28m
  • Richard Cheeseman (46yo)

    Head of Engineering & Facilities

    • Tenure: 0yrs
  • Pratap Rudra

    Company Secretary

    • Tenure: 2.7yrs
    • Compensation: ₹3.11m

Board Members

  • Narayan Seshadri (62yo)

    Independent Chairman of the Board

    • Tenure: 2.8yrs
    • Compensation: ₹1.00m
  • Revathy Ashok (60yo)

    Independent Non-Executive Director

    • Tenure: 2.8yrs
  • Ian Parish (47yo)

    Non-Executive Director

    • Tenure: 2.2yrs
  • Gagan Bedi (48yo)

    MD, Country President & Executive Director

    • Tenure: 2.3yrs
    • Compensation: ₹38.13m
  • Rajesh Marwaha (56yo)

    CFO & Executive Director

    • Tenure: 2.8yrs
    • Compensation: ₹19.72m
  • Kimsuka Narsimhan (55yo)

    Independent Non-Executive Director

    • Tenure: 0yrs
    • Compensation: ₹600.00k
  • Revathy Ashok (60yo)

    Independent Non-Executive Director

    • Tenure: 2.8yrs
    • Compensation: ₹1.00m
  • Weiying Sarah Wang (44yo)

    Non-Executive Director

    • Tenure: 0.6yrs

Company Information

AstraZeneca Pharma India Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AstraZeneca Pharma India Limited
  • Ticker: 506820
  • Exchange: BSE
  • Founded: 1979
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹54.971b
  • Shares outstanding: 25.00m
  • Website: https://www.astrazeneca.com/india

Number of Employees


Location

  • AstraZeneca Pharma India Limited
  • Manyata Embassy Business Park
  • Block N1, 12th Floor
  • Bengaluru
  • Karnataka
  • 560045
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
506820BSE (Mumbai Stock Exchange)YesEquity SharesININRJul 2000
ASTRAZENNSEI (National Stock Exchange of India)YesEquity SharesININRJul 2000

Biography

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and distributes pharmaceutical products in India and internationally. The company offers products in the areas of cardi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 12:41
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.